[5] Gong Y, Li X, Ma X, et al. Lipid goal attainment in post-acute coronary syndrome patients in China: Results from the 6-month real-world dyslipidemia international study II [J]. Clinical cardiology, 2021, 4...
1、 降低降低ldl的策略的策略北京医院心内科北京医院心内科赵迎赵迎内皮功能内皮功能受损受损炎症反应增加炎症反应增加平滑肌细胞平滑肌细胞增殖和迁移增殖和迁移形成纤维帽形成纤维帽ldlldl进入内进入内皮下被氧化皮下被氧化巨噬细胞巨噬细胞吞噬吞噬oxoxldlldl形成泡沫细胞形成泡沫细胞 斑块破裂局部斑块破裂局部 血小板聚集...
The 2019 ESC/EAS Dyslipidemia Guidelines recommend an LDL-C goal of <1.4 mmol/L (55 mg/dl) for patients with very high-risk ASCVD, and <1 mmol/L (40 mg/dl) for those with recurrent events within 2 years despite taking maximally tolerated statin therapy. The addition of PCSK9 ...
However, target LDL-C levels continue to be lowered. Specifically, the goal of maintaining LDL-C at or below 55 mg/dL was established because several clinical studies have shown evidence that LDL-C reduction provides additional clinical benefit. With the recent increase in the use of PCSK9 inh...
Attainment of treatment goals was defined according to 2016 ESC guidelines for the management of dyslipidemia: LDL-C < 70 mg/dl and HbA1c < 7.0%.2 An LDL-C treatment goal of <55 mg/dl according to ...
The main goal of a treatment program is to lower total cholesterol levels, LDL ("bad") cholesterol levels, and triglyceride levels. Treatment may cause a slight rise in HDL or good cholesterol in the blood. There are two main ways to control cholesterol; lifestyle changes, and medication. ...
In the ODYSSEY ALTER- NATIVE trial, alirocumab produced greater LDL-C reduction compared with ezetimibe in patients intolerant to statins (45% and 14.6% at week 24, respectively), and a higher percentage of patients reached the recommended LDL-C goal (41.9% vs 4.4%, respectively) (Moriarty ...
For very high-risk CV disease, the treatment goal is ≥ 50% reduction from baseline LDL-C and on-treatment LDL-C of < 1.4 mmol/L (< 55 mg/dL), with treatment recommendations of high-intensity statin with or without ezetimibe. If the treatment goal has been reached in very high...
My current goal is to address the root causes of the rT3 dominance and wean myself off the T3 supplement. I hope to achieve this in the next few months. My working hypothesis is that the cause of my high rT3 / low T3 was some combination of very low carb dieting, elevated cortisol ...
Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2003;18:220-228. Major coronary event, unstable angina,...